Parkinson's disease (PD) is a chronic neurodegenerative disorder mainly attributed to the progressive loss of dopaminergic neurons in the substantia nigra, which leads to uncontrolled voluntary movements causing tremors, postural instability, joint stiffness, and speech and locomotion difficulties, among other symptoms. Previous studies have shown the participation of specific peptides in neurodegenerative diseases. In this context, the present work analyzed changes in the peptide profile in zebrafish brain induced to parkinsonian conditions with 6-hydroxydopamine, using isotopic labeling techniques plus mass spectrometry. These analyses allowed the relative quantitation and identification of 118 peptides. Of these, nine peptides showed significant changes, one peptide was increased and eight decreased. The most altered sequences were fragment of cytosolic and extracellular proteins related to lipid metabolism and dynamic cytoskeleton. These results open new perspectives of study about the function of peptides in PD.
Get full access to this article
View all access options for this article.
References
1.
DorseyER, ConstantinescuR, ThompsonJP, et al.Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007; 68:384–386.
2.
WirdefeldtK, AdamiHO, ColeP, TrichopoulosD, MandelJ. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol, 2011; 26Suppl 1:S1–S58.
LiuJ, LiuW, LuY, et al.Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy, 2018; 14:845–861.
11.
Segura-AguilarJ, ParisI, MuñozP, FerrariE, ZeccaL, ZuccaFA. Protective and toxic roles of dopamine in Parkinson's disease. J Neurochem, 2014; 129:898–915.
12.
PickrellAM, YouleRJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron, 2015; 85:257–273.
13.
XicoyH, WieringaB, MartensGJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener, 2017; 12:10.
14.
ChenXY, DuYF, ChenL. Neuropeptides exert neuroprotective effects in Alzheimer's disease. Front Mol Neurosci, 2019; 11:493.
15.
RoseJB, CrewsL, RockensteinE, et al.Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J Neurosci, 2009; 29:1115–1125.
16.
BaiulaM, BediniA, SpampinatoSM. Role of nociceptin/orphanin FQ in thermoregulation. Neuropeptides, 2015; 50:51–56.
17.
MuroiY, IshiiT. A novel neuropeptide Y neuronal pathway linking energy state and reproductive behavior. Neuropeptides, 2016; 59:1–8.
18.
BlasiakA, GundlachAL, HessG, LewandowskiMH. Interactions of circadian rhythmicity, stress and orexigenic neuropeptide systems: implications for food intake control. Front Neurosci, 2017; 11:127.
LindenR, MartinsRA, SilveiraMS. Control of programmed cell death by neurotransmitters and neuropeptides in the developing mammalian retina. Prog Retin Eye Res, 2005; 24:457–491.
21.
ReglodiD, RenaudJ, TamasA, et al.Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol, 2017; 155:120–148.
22.
DexterDT, JennerP. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med, 2013; 62:132–144.
23.
de AraujoCB, RussoLC, CastroLM, et al.A novel intracellular peptide derived from g1/s cyclin d2 induces cell death. J Biol Chem, 2014; 289:16711–16726.
24.
BahdoudiS, GhouiliI, HmidenM, et al.Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. Cell Mol Life Sci, 2018; 75:2075–2091.
25.
WangG, PanJ, TanYY, et al.Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. Neuropeptides, 2008; 42:267–276.
26.
ReglodiD, AtlaszT, JunglingA, et al.Alternative routes of administration of the neuroprotective pituitary adenylate cyclase activating polypeptide. Curr Pharm Des, 2018; 24:3892–3904.
27.
SarkarS, DammerEB, MalovicE, et al.Molecular signatures of neuroinflammation induced by αSynuclein aggregates in microglial cells. Front Immunol, 2020; 11:33.
28.
Van CampKA, BaggermanG, BlustR, HussonSJ. Peptidomics of the zebrafish Danio rerio: in search for neuropeptides. J Proteomics, 2017; 150:290–296.
29.
TeixeiraCMM, CorreaCN, IwaiLK, FerroES, CastroLM. Characterization of intracellular peptides from zebrafish (Danio rerio) brain. Zebrafish, 2019; 16:240–251.
30.
HeimannAS, GiardiniAC, Sant'AnnaMB, et al.NFKF is a synthetic fragment derived from rat hemopressin that protects mice from neurodegeneration. Neurosci Lett, 2020; 721:134765.
31.
RussoLC, CastroLM, GozzoFC, FerroES. Inhibition of thimet oligopeptidase by siRNA alters specific intracellular peptides and potentiates isoproterenol signal transduction. FEBS Lett, 2012; 586:3287–3292.
32.
BlesaJ, PhaniS, Jackson-LewisV, PrzedborskiS. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol, 2012; 2012:845618.
33.
LeW, SayanaP, JankovicJ. Animal models of Parkinson's disease: a gateway to therapeutics?. Neurotherapeutics, 2014; 11:92–110.
34.
MatsuiH, SugieA. An optimized method for counting dopaminergic neurons in zebrafish. PLoS One, 2017; 12:e0184363.
35.
HoweK, ClarkMD, TorrojaCF, et al.The zebrafish reference genome sequence and its relationship to the human genome. Nature, 2013; 496:498–503.
36.
KalueffAV, StewartAM, GerlaiR. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol Sci, 2014; 35:63–75.
37.
DuY, GuoQ, ShanM, et al.Spatial and temporal distribution of dopaminergic neurons during development in zebrafish. Front Neuroanat, 2016; 10:115.
38.
MatsuiH, ItoH, TaniguchiY, InoueH, TakedaS, TakahashiR. Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J Neurochem, 2010; 115:178–187.
39.
RodriguezA, ZhangH, KlaminderJ, BrodinT, AnderssonPL, AnderssonM. ToxTrac: a fast and robust software for tracking organisms. Methods Ecol Evol, 2018; 9:460–464.
40.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72:248–254.
GewehrMCF, TeixeiraAAS, SantosBAC, et al.The relevance of thimet oligopeptidase in the regulation of energy metabolism and diet-induced obesity. Biomolecules, 2020; 10:321.
43.
MaB, ZhangK, HendrieC, et al.PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom, 2003; 17:2337–2342.
44.
ZhangJ, XinL, ShanB, et al.PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol Cell Proteomics, 2012; 11:M111.010587.
45.
TinocoAD, SaghatelianA. Investigating endogenous peptides and peptidases using peptidomics. Biochemistry, 2011; 50:7447–7461.
46.
FrickerLD. Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins. Mol Biosyst, 2010; 6:1355–1365.
47.
BerezniukI, SironiJ, CallawayMB, et al.CCP1/Nna1 functions in protein turnover in mouse brain: implications for cell death in Purkinje cell degeneration mice. FASEB J, 2010; 24:1813–1823.
48.
DasguptaS, YangC, CastroLM, et al.Analysis of the yeast peptidome and comparison with the human peptidome. PLoS One, 2016; 11:e0163312.
49.
DasguptaS, FishmanMA, CastroLM, TashimaAK, FerroES, FrickerLD. Effect of protein denaturation and enzyme inhibitors on proteasomal-mediated production of peptides in human embryonic kidney cells. Biomolecules, 2019; 9:207.
50.
GelmanJS, SironiJ, BerezniukI, et al.Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One, 2013; 8:e53263.
51.
FrickerLD, GelmanJS, CastroLM, GozzoFC, FerroES. Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides. J Proteome Res, 2012; 11:1981–1990.
52.
BerezniukI, SironiJJ, WardmanJ, et al.Quantitative peptidomics of Purkinje cell degeneration mice. PLoS One, 2013; 8:e60981.
53.
OwadaY, AbdelwahabSA, KitanakaN, et al.Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene. Eur J Neurosci, 2006; 24:175–187.
54.
OwadaY. Fatty acid binding protein: localization and functional significance in the brain. Tohoku J Exp Med, 2008; 214:213–220.
55.
IslamA, KagawaY, MiyazakiH, et al.FABP7 protects astrocytes against ROS toxicity via lipid droplet formation. Mol Neurobiol, 2019; 56:5763–5779.
56.
KawahataI, BoussetL, MelkiR, FukunagaK. Fatty acid-binding protein 3 is critical for α-synuclein uptake and MPP+-induced mitochondrial dysfunction in cultured dopaminergic neurons. Int J Mol Sci, 2019; 20:5358.
57.
YabukiY, MatsuoK, KawahataI, et al.Fatty acid binding protein 3 enhances the spreading and toxicity of α-synuclein in mouse brain. Int J Mol Sci, 2020; 21:2230.
58.
IoannouMS, JacksonJ, SheuSH, et al.Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell, 2019; 177:1522–1535.e14.
59.
LiuL, MacKenzieKR, PutluriN, Maletić-SavatićM, BellenHJ. The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab, 2017; 26:719–737.e6.
60.
ZhangJ, SokalI, PeskindER, et al.CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol, 2008; 129:526–529.
61.
Perez-GraciaE, BlancoR, CarmonaM, CarroE, FerrerI. Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathol, 2009; 118:497–504.
62.
McCombM, KrikheliM, UherT, et al.Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. J Clin Lipidol, 2020; 14:675–684.e2.
63.
GaoJ, HuangX, ParkY, et al.Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging, 2011; 32:2106.e1–e6.
64.
MataIF, LeverenzJB, WeintraubD, et al.APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol, 2014; 71:1405–1412.
65.
TsuangD, LeverenzJB, LopezOL, et al.APOE ɛ4 increases risk for dementia in pure synucleinopathies. JAMA Neurol, 2013; 70:223–228.
66.
El AmriM, FitzgeraldU, SchlosserG. MARCKS and MARCKS-like proteins in development and regeneration. J Biomed Sci, 2018; 25:43.
67.
BrudvigJJ, WeimerJM. X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease. Front Cell Neurosci, 2015; 9:407.
68.
GoldsteinAL, HannappelE, KleinmanHK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 2005; 11:421–429.
69.
MorrisDC, ZhangZG, ChoppM. Thymosin β4 for the treatment of acute stroke: neurorestorative or neuroprotective?. Expert Opin Biol Ther, 2018; 18(sup1):149–158.
70.
XiongY, MahmoodA, MengY, et al.Treatment of traumatic brain injury with thymosin β₄ in rats. J Neurosurg, 2011; 114:102–115.
71.
ZhangJ, ZhangZG, MorrisD, et al.Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience, 2009; 164:1887–1893.
72.
XiongY, MahmoodA, MengY, et al.Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci, 2012; 1270:51–58.
73.
FatimaMT, IslamZ, AhmadE, SalahuddinP. Emerging targets and latest proteomics based therapeutic approaches in neurodegenerative diseases. Curr Protein Pept Sci, 2018; 19:858–875.
74.
SantiagoJA, BotteroV, PotashkinJA. Dissecting the molecular mechanisms of neurodegenerative diseases through network biology. Front Aging Neurosci, 2017; 9:166.
75.
JohnsonMD, YuLR, ConradsTP, et al.The proteomics of neurodegeneration. Am J Pharmacogenomics, 2005; 5:259–270.
76.
FrickerLD. Carboxypeptidase E and the identification of novel neuropeptides as potential therapeutic targets. Adv Pharmacol, 2018; 82:85–102.
77.
NilssonA, FälthM, ZhangX, et al.Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol Cell Proteomics, 2009; 8:1094–1104.
78.
Cafe-MendesCC, FerroES, BrittoLR, Martins-de-SouzaD. Using mass spectrometry-based peptidomics to understand the brain and disorders such as Parkinson's disease and schizophrenia. Curr Top Med Chem, 2014; 14:369–381.
79.
SharmaK, SchmittS, BergnerCG, et al.Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci, 2015; 18:1819–1831.
80.
NolteH, KonzerA, RuhsA, JungblutB, BraunT, KrügerM. Global protein expression profiling of zebrafish organs based on in vivo incorporation of stable isotopes. J Proteome Res, 2014; 13:2162–2174.
81.
EdsonAJ, HushagenHA, FrøysetAK, et al.Dysregulation in the brain protein profile of zebrafish lacking the Parkinson's disease-related protein DJ-1. Mol Neurobiol, 2019; 56:8306–8322.
82.
HoB, BaryshnikovaA, BrownGW. Unification of protein abundance datasets yields a quantitative Saccharomyces cerevisiae proteome. Cell Syst, 2018; 6:192–205.e3.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
